1. Pink Sheet
  2. >>Geography
  3. >>North America

Still Cloudy: CMS “Hopeful” Some Sunshine Data Collection Begins In 2013

 
• By Cathy Kelly

CMS is still unable to provide certainty regarding the timeline for releasing a final rule implementing the Sunshine Act, Policy and Data Analysis Group Director Niall Brennan told a congressional roundtable on the issue Sept. 12.

The Centers for Medicare and Medicaid Services is hoping that final regulations implementing the Sunshine Act will be out in enough time to allow manufacturers to begin collecting data during 2013 on payments and “transfers of value” to physicians and teaching hospitals, CMS Policy and Data Analysis Group Director Niall Brennan told a congressional roundtable on the issue Sept. 12.

However, Brennan was careful to point out he couldn’t say for sure that the rule will be done within that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By Tim Casey

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Drug Sponsors Can Help Shape Agenda For FDA/EMA Pediatric ‘Cluster’ Calls

 
• By Sue Sutter

Companies can propose specific issues for discussion during the regulators’ monthly teleconferences, which focus on finding areas of agreement and reasons for nonalignment on specific pediatric development plans or general issues.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.